PETAH-TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, reported today that a significant decrease in HCV viral load was noted in a patient with liver cancer treated daily, orally with CF102, within the framework of a Phase I/II clinical study in liver cancer (hepatocellular carcinoma, HCC) patients.
